[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-353058-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-353058-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","the-role-of-luteolin-naringenin-and-scutellarin-in-breast-cancer-inhibition-of-hdac4hdac8","The role of Luteolin, Naringenin, and Scutellarin in breast cancer - inhibition of HDAC4/HDAC8","","Side effects from conventional cancer therapies drive the search for safer alternatives. This study evaluates three flavonoids—Luteolin, Naringenin, and Scutellarin—focusing on molecular target identification in human breast cancer. Candidate targets were screened via ePharmaLib, followed by in silico pharmacophore mapping and molecular docking. Enzyme inhibition was confirmed with HDAC4/HDAC8 assays and the work demonstrates apoptosis induction, stronger cytotoxicity for Luteolin, radical scavenging, catalase enhancement, and reduced LPS-triggered inflammation in THP-1-derived macrophages through lower pro-inflammatory cytokines.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/the-role-of-luteolin-naringenin-and-scutellarin-in-breast-cancer-inhibition-of-hdac4hdac8/353058/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/the-role-of-luteolin-naringenin-and-scutellarin-in-breast-cancer-inhibition-of-hdac4hdac8/353058.png","ImageObject",300,407,{"name":42,"@type":43},"Mabel","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-29","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",11,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What flavonoids were studied for breast cancer treatment potential?","Question",{"text":63,"@type":64},"The study investigated Luteolin, Naringenin, and Scutellarin and assessed their anticancer, antioxidant, and anti-inflammatory activities.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were molecular targets identified and validated?",{"text":68,"@type":64},"Potential targets were screened with ePharmaLib, then evaluated using in silico pharmacophore mapping and molecular docking. HDAC4/HDAC8 inhibition was confirmed using in vitro biochemical assays and cell-based studies.",{"name":70,"@type":61,"acceptedAnswer":71},"What was the main enzyme target confirmed for these flavonoids?",{"text":72,"@type":64},"HDAC4 and HDAC8 were validated as enzyme targets, with Luteolin showing particularly strong inhibition and potency in breast cancer cell lines.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},353058,1790192657,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":146,"preview_page_count":33,"preview_urls":147},7971474920318,"https://ap-avatar.wpscdn.com/avatar/74000ee537e6b0ca360?x-image-process=image/resize,m_fixed,w_180,h_180&k=1788430171632181674","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nThe role of Luteolin, Naringenin, and Scutellarin in breast cancer by inhibition of HDAC4/HDAC8  \nSujata Mishra1, Sai Ananya PavaniA2, AparnaVema1􀀍 & Arunasree M. Kalle1􀀍  \nThe side effects associated with conventional anti-cancer therapies call for safer and more effective alternatives. Flavonoids are a class of polyphenolic compounds well documented to possess antioxidant, anti-inflammatory, and anticancer properties. This study investigates the bioactivity of three flavonoids, namely Luteolin, Naringenin, and Scutellarin, with a focus on identification and validation of their molecular targets in human breast cancer. Potential targets were screened using theePharmaLib database, followed by in silico structure-based pharmacophore mapping and molecular docking. Further confirmation was achieved through in vitro biochemical assays and cell-based studies. HDAC4 and HDAC8 assays validated the enzyme inhibitions of flavonoids, particularly Luteolin. In breast cancer cell lines, apoptosis was induced by flavonoids, as viewed by fluorescence microscopy and flow cytometry. Among these, Luteolin exhibited the most potent cytotoxicity. Antioxidant activity assays showed that luteolin and Scutellarin strongly scavenged radicals similar to quercetin. Naringenin and Luteolin significantly enhanced catalase activity. InTHP-1-derived macrophages, all three flavonoids significantly suppressed LPS-induced inflammation with reduced expression of pro-inflammatory cytokines at both RNA and protein levels. Collectively, results clearly pinpoint that Luteolin, Naringenin, and Scutellarin may be explored as therapeutic possibilities since they exhibit strong anticancer, antioxidant, and anti-inflammatory properties.  \nKeywords Flavonoids, Breast cancer, Antioxidant, Anti-inflammatory, Anticancer, Histone deacetylase  \nBreast cancer remains one of the most common malignancies in women worldwide. It poses certain therapeutic challenges, despite improvements in current treatments. Although chemotherapy and radiation therapy are effective standard interventions, they are often associated with serious side effects, such as neuropathy, immunosuppression, and drug resistance1. Among natural products, phytochemicals, especially flavonoids, have garnered significant attention due to their diverse and potent pharmacological activities. Flavonoids are polyphenolic secondary metabolites present in fruits, vegetables, leaves, and seeds. Flavonoids have abenzopyrone backbone with variable phenolic substitutions and are synthesised through the phenylpropanoid pathway1. They are generally classified into seven subtypes: flavones, flavonols, flavanones, isoflavones, anthocyanidins, flavanols, and chalcones2.  \nThese flavonoids represent a wide range of biological activities, including anticancer3, anti-inflammatory4, antioxidant, antiviral, and cardioprotective effects. The anticancer efficacy of these flavonoids is attributed to several mechanisms, which may involve ROS scavenging, chelation of metal ions, activation of antioxidant defences, and modulation of various signalling pathways that participate in apoptosis, angiogenesis, or carcinogen detoxification3.  \nCompounds such as Quercetin5, Luteolin6, and Kaempferol7 have exhibited the potential to cause apoptosis in cancerous cells and, hence, are considered anticancer agents.  \nFor this study, we chose three structurally diverse flavonoids, namely Luteolin, Naringenin, and Scutellarin, with known bioactive potential and possessing structural similarity to Quercetin.  \nLuteolin is a flavone widely found in celery, broccoli, carrots, onion leaves, and chrysanthemum flowers. It generally exists in glycosidic form. It is a potent ROS inhibitor, with wide biological activity8.  \nNaringenin is a flavanone known for its therapeutic effects in inflammatory diseases, sepsis, fibrosis, diabetes, insulin resistance, and cancer. It is widely ","cbCaiecgjxo8Ci5W","https://ap.wps.com/l/cbCaiecgjxo8Ci5W","pdf",5913886,17,"English","# Results\n## In silico target identification: HDAC4 and HDAC8\n## Molecular docking validation\n## Biological effects in breast cancer and macrophages","[{\"question\":\"What flavonoids were studied for breast cancer treatment potential?\",\"answer\":\"The study investigated Luteolin, Naringenin, and Scutellarin and assessed their anticancer, antioxidant, and anti-inflammatory activities.\"},{\"question\":\"How were molecular targets identified and validated?\",\"answer\":\"Potential targets were screened with ePharmaLib, then evaluated using in silico pharmacophore mapping and molecular docking. HDAC4/HDAC8 inhibition was confirmed using in vitro biochemical assays and cell-based studies.\"},{\"question\":\"What was the main enzyme target confirmed for these flavonoids?\",\"answer\":\"HDAC4 and HDAC8 were validated as enzyme targets, with Luteolin showing particularly strong inhibition and potency in breast cancer cell lines.\"}]","The role of Luteolin, Naringenin, and Scutellarin in breast cancer - inhibition of HDAC4/HDAC8 | PDF",1790102780,43,[148,152,156,160],{"page_no":22,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c9174e5078021a889e0761fc81cc3433.webp",983,1291,{"page_no":26,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0b1defc8a613a59c1a3b09bd669e02d8.webp",982,1290,{"page_no":30,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e7fc74889b81472de60e7021ab9a9179.webp",981,1289,{"page_no":33,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c53fa29189c56e65fac7760ce335e347.webp",980,1287]